106 related articles for article (PubMed ID: 2210687)
1. Combination of interferon and dexamethasone in refractory multiple myeloma.
San Miguel JF; Moro M; Bladé J; Guerras L; Hernandez J; Jimenez-Galindo R; Ortega F; Gonzalez M
Hematol Oncol; 1990; 8(4):185-9. PubMed ID: 2210687
[TBL] [Abstract][Full Text] [Related]
2. Recombinant interferon-alpha 2b and high dose methyl prednisolone in relapsed and resistant multiple myeloma.
Ganjoo RK; Johnson PW; Evans ML; Williams A; Rohatiner AZ; Lister TA; Malpas JS
Hematol Oncol; 1993; 11(4):179-86. PubMed ID: 8144132
[TBL] [Abstract][Full Text] [Related]
3. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
4. Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan.
Wada M; Mizoguchi H; Kuriya SI; Taguchi H; Kawamura T; Maekawa I; Shimazaki C; Sato Y; Niho Y; Miyazaki T; Shibata A; Kitani T; Hamajima N; Ohno R
Br J Haematol; 2000 Jun; 109(4):805-14. PubMed ID: 10929034
[TBL] [Abstract][Full Text] [Related]
5. Interferon and dexamethasone in multiple myeloma patients refractory to chemotherapy.
San Miguel JF; Moro M; Bladé J; Guerras L; Hernandez J; Jiminez-Galindo R; Ortega F; Gonzalez M
Eur J Cancer; 1991; 27 Suppl 4():S48-9. PubMed ID: 1799478
[No Abstract] [Full Text] [Related]
6. A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma.
Hübel K; Tesch H; Kröger B; Schnell R; Borchmann P; Diehl V; Engert A
Leukemia; 1997 Dec; 11 Suppl 5():S47-51. PubMed ID: 9436939
[TBL] [Abstract][Full Text] [Related]
7. [New protocols for myeloma chemotherapy plus IFN alpha].
Kitani T
Rinsho Ketsueki; 1993 Apr; 34(4):455-9. PubMed ID: 8510333
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
9. Modified adriamycin-vincristine-dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. The National Cancer Institute of Canada Clinical Trials Group.
Browman GP; Belch A; Skillings J; Wilson K; Bergsagel D; Johnston D; Pater JL
Br J Haematol; 1992 Nov; 82(3):555-9. PubMed ID: 1486035
[TBL] [Abstract][Full Text] [Related]
10. [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma].
Gao W; An N; Chen SL
Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):221-2. PubMed ID: 16624158
[TBL] [Abstract][Full Text] [Related]
11. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
13. All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma.
Musto P; Sajeva MR; Sanpaolo G; D'Arena G; Scalzulli PR; Carotenuto M
Haematologica; 1997; 82(3):354-6. PubMed ID: 9234591
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma.
Dimopoulos MA; Weber D; Delasalle KB; Alexanian R
Cancer; 1993 Nov; 72(9):2589-92. PubMed ID: 8402480
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.
Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C
J BUON; 2007; 12(1):41-4. PubMed ID: 17436400
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of multiple myeloma with high-dose chemotherapy and transplantation of autologous hematopoietic stem cells and subsequent maintenance therapy with interferon alfa-2b or interferon alfa 2b and dexamethasone. Report of the ongoing study of the "4W" Czech Myeloma Group].
Adam Z; Krejcí M; Bacovský J; Hejlová N; Kuca B; Svojgrová M; Franková H; Gumulec J; Janca J; Veprek K; Januska B; Lehanka F; Rezek Z; Praskac P; Cahová S; Vránová M; Papajík T; Králová E; Novotná J; Scudla V; Koza V; Drbal J; Faber E; Mareschová I; Hájek R
Vnitr Lek; 1998 Jul; 44(7):400-8. PubMed ID: 9748876
[TBL] [Abstract][Full Text] [Related]
18. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Dimopoulos MA; Goldschmidt H; Niesvizky R; Joshua D; Chng WJ; Oriol A; Orlowski RZ; Ludwig H; Facon T; Hajek R; Weisel K; Hungria V; Minuk L; Feng S; Zahlten-Kumeli A; Kimball AS; Moreau P
Lancet Oncol; 2017 Oct; 18(10):1327-1337. PubMed ID: 28843768
[TBL] [Abstract][Full Text] [Related]
19. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
[TBL] [Abstract][Full Text] [Related]
20. Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Yee AJ; Bensinger WI; Supko JG; Voorhees PM; Berdeja JG; Richardson PG; Libby EN; Wallace EE; Birrer NE; Burke JN; Tamang DL; Yang M; Jones SS; Wheeler CA; Markelewicz RJ; Raje NS
Lancet Oncol; 2016 Nov; 17(11):1569-1578. PubMed ID: 27646843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]